Medical Bills Still Cause Bankruptcy. AI Is Here to Help With Your Colonoscopy.

A Bluesky user put it with the economy of someone who has said this before and expects not to be heard: "Medical bills are the top reason bankruptcy is filed. AI will fix everything but can't figure out this simple issue?" One like. No replies. The post vanished into a feed full of market size projections and bootcamp announcements, which is precisely the point.

The healthcare AI conversation right now is running on two separate tracks that don't intersect. On one, news outlets and crypto-adjacent accounts are bullish: an AI medical imaging market projected to reach nearly $22 billion, a blockchain-health startup called XRPH AI described by its promoters as "already live and expanding in real-world healthcare," researchers publishing multimodal colonoscopy datasets in Machine Intelligence Research. On the other track, Bluesky users are watching segments about AI's perils in medicine and reposting Stanford-Harvard research showing that severe patient harm remained possible in more than one in five cases tested — often not through wrong answers, but through omission, the AI simply not flagging what it didn't know to flag. The two tracks share vocabulary but are describing entirely different things when they say "healthcare AI."

What makes the Bluesky bankruptcy post worth sitting with isn't the snark — it's the implied argument. AI in healthcare is being developed and funded at the level of the dramatic: cancer diagnosis, imaging analysis, personalized drug-digital therapeutic hybrids. The system failures that produce medical bankruptcy are structural, political, and boring in the way that only decades of policy failure can be boring. You can't demo a fix to insurance billing at a conference. You can demo a vision-language model that identifies polyps. So that's what gets built, funded, and announced. The critics on Bluesky aren't wrong that this is a choice, even if no individual researcher making it is acting in bad faith.

The NOHARM study finding — severe harm possible in up to 22% of cases, through omission — deserves more attention than it's getting in the optimistic coverage. An AI that confidently answers the question you asked while missing the condition you didn't think to ask about isn't a diagnostic tool; it's a liability dressed as a feature. The news cycle is already moving toward market projections and summer bootcamps for high schoolers. The people who will eventually be harmed by a confident omission probably aren't on Bluesky either. They're just patients, which is the oldest way to be ignored by a healthcare system, and apparently also the newest.